Comparison of CYFRA 21-1, CEA, CA 19-9 and CA 72-4 levels in gastric cancer

Öz

Objective: Gastric cancer is the fourth most common malignancy, and the second most common cause of cancer mortality worldwide. The aim of this study was to investigate the role of biomarkers CYFRA 21-1, CA 19-9, CEA, CA72.4 at diagnosis and throughout the follow-up in patients with gastric cancer. Methods: 30 patients with gastric cancer diagnosed and 31 healthy people as a control group were included in this study. According to the TNM staging system, there were 16 patients with stage II and 14 patients with stage III in the group of patients with gastric cancer. CEA, CA 19-9, CA 72-4 and CYFRA 21-1 levels were studied by elektrochemiluminescence immunasay (ECLIA) method in the Cobas e 601 instrument. Results: Statistically the level of CA 72-4, CA 19-9, CEA and CYFRA 21-1 gastric cancer groups was found significant high accaording to healthy control group (p

Anahtar Kelimeler

• Gastric cancer
• tumor markers
• CYFRA 21-1

Mide kanserinde CYFRA 21-1, CEA, CA 19-9 ve CA 72-4 düzeylerinin karşılaştırılması

Öz

Amaç: Mide kanseri dördüncü en sık görülen kanser olup, dünyada kanser ölümlerinin ikinci en sık nedenidir. Bu çalışmada mide kanserinin tanı ve takibinde tümör markırları olan CYFRA 21-1, CA 19-9, CEA ve CA 72-4’ün rollerinin araştırılması amaçlandı.
Yöntemler: Çalışmamıza mide kanseri tanısı almış 30 hasta ve 30 sağlıklı birey alındı. Mide kanserli hasta grubunun TNM evrelendirme sistemine göre 16’sı Evre II, 14’ü Evre III idi. CEA, CA 19-9, CA 72-4 ve CYFRA 21-1 düzeyleri, elektrochemiluminescence immunasay (ECLIA) metod ile Cobas e 601 cihazında çalışıldı.
Bulgular: Mide kanserli hasta grubunun CA 72-4, CA 19- 9, CEA ve CYFRA 21-1 düzeyleri sağlıklı kontrol grubuna göre istatistiksel olarak anlamlı yüksek bulundu (p<0.01). Mide kanserli hastalarda Evre III hasta grubunun CA 19- 9, CEA ve CYFRA 21-1 düzeyleri Evre II hasta grubuna göre istatistiksel olarak anlamlı yüksek bulundu (p<0.01). Tümör markırların kesim değerleri (cut-off), sensitivitesi ve spesifitesi sırayla; CEA için 4.15 ng/mL, %46 ve %96; CA 19-9 için 24.50 U/mL, %17 ve %96; CA 72-4 için 2.46 U/mL, %53 ve %96 ve CYFRA 21-1 için 3.36 ng/mL, %46 ve %100 bulundu.
Sonuç: Çalışmamızda mide kanserli hastaların takibinde CYFRA 21-1, CEA ve CA 72-4’ ün değerli olduğunu saptadık. 

Anahtar Kelimeler

• Mide kanseri
• tümör belirteçleri
• CYFRA 21-1

Kaynakça

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statis- tics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Bodenmueller H, Ofenloch-Hahnle B, Lane EB, Dessauer A. Lung Cancer associated Keratin 19 Fragments: Devel- opment and Biochemical Characterization of the new Se- rum Assay Enzymun- Test Cyfra 21-1. Int J Biol Markers 1994;9:75-81.
3. Bodenmueller H. The biochemistry of Cyfra 21-1 and other cytokeratin-tests. Scand J Clin Lab Suppl Invest 1995;221:60-66.
4. Stieber P, Dienemann H, et al. Comparison of Cytokera- tin Fragment 19 (Cyfra 21-1) Tissue Polypeptide Antigen (TPA) and Tissue Polypeptide Specific Antigen (TPS) as Tumor Markers in Lung Cancer. Eur J Clin Chem Clin Bio- chem 1993;31:689-694.
5. Bodenmueller H, Donie F, Kaufmann M, Banauch D. The tumor markers TPA, TPS TPACYK and Cyfra 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994;9:70-74.
6. Stieber P, Hasholzner U, et al. Cyfra 21-1: A new marker in lung cancer. Cancer 1993;72:707-713.
7. Grem J. The prognostic importance of tumor markers in ade- nocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997;4:380-387.
8. Kirkwood KS, Khitin LM, Barwick KW. Prognostic indi- cators for cancer. Gastric cancer. Surg Oncol Clin N Am 1997;6:495-514.

9. Micali B, Florio MG, Venuti A, et al. Usefulness of carcino- embryonic antigen measurement in gastric juice of patients with gastric disorders. J Clin Gastroenterol 1983;5:411-415.
10. Piantino P, Taccone W, Fusaro A, et al. Significance of CA 72.4 serum levels in gastrointestinal diseases. Int J Biol Markers 1990;5:77-80.
11. Göral V, Yeşilbağdan H, et al. Mide kanserinde yeni bir tümör markeri olan CA 72-4’ün yeri. Turkiye Klinikleri J Med Sci 2006;26:3-8.
12. Stephen B. Edge,carolyn C. Compton, The American Joint Committee on Cancer: the 7 th edition of the AJCC cancer staging Manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
13. Joypaul B, Browning M, Newman E, et al. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg 1995;169:595- 599.
14. Kodama I, Koufuji K, Kawabata S, et al. The clinical effi- cacy of CA 72-4 as serum marker for gastric cancer in com- parison with CA 19-9 and CEA. Int Surg 1995;80:45-48.
15. Nakata B, Chung YS, et al. Clinical significance of serum Cyfra 21-1 in gastric cancer. British Journal of Cancer 1996;73:1529-1532.
16. Byrne DJ, Browning MC, Cuschieri A. CA 72-4: A new tumor marker for gastric cancer. Br J Surg 1990;77:1010- 1013.
17. Stieber P, Bodenmuller H, Banauch D, et al. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin. Biochem 1993;26:301-304.
18. Marrelli D, Roviello F, De Stefano A, et al. Prognostic sig- nificance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in in gastric carcinoma. Oncology 1999;57:55-62.